 |
| Aaron Goldman, PhD |
Aaron Goldman, PhD, of the Division of Engineering in Medicine, entered into a sponsored research agreement with Cannex Scientific Inc. to fund a research project that will assess the neurophysiological, gastroesophageal, behavioral and antiviral therapeutic properties of cannabis. The team has already uncovered novel use of cannabinoids in one of these therapeutic areas.
The grant will provide the Brigham, and Goldman’s research team, with $1.5 million over two years. In his study, Goldman will collaborate with co-investigators, Luke P. Lee, PhD, of the Division of Engineering in Medicine, and Ilana Braun, MD, chief of Psychosocial Oncology at Dana-Farber Cancer Institute. Together, the team brings a confluence of expertise in clinical medicine, bioengineering and multiple disease models for screening therapeutic efficacy.
More broadly at the Brigham, Goldman's research is focused on response and resistance to therapy using animal models, molecular systems biology, and using computational and mathematical tools to interrogate the molecular mechanisms of biology and disease.
Cannex Scientific Inc. is a biopharmaceutical company focused on unleashing the power of the endocannabinoid system to address large global unmet health challenges through the development of cannabinoid-based therapeutics.
